The exit strategies of life sciences companies have become more varied due to the current situation being experienced by global capital markets. This is primarily the case for German life sciences companies as well. The choice of exit scenario must be made carefully based on the individual circumstances of the company. The panelists will present and discuss the different exit variations and commercialization strategies, specifically when considering exits of German life sciences companies in other countries (such as the United States or Switzerland)
Collaboration Deals
Joint Ventures
Staged Exits
Milestone Agreements
Indemnification vs. Warranties
Sub-licensing structures
Big pharma deal terms
Speakers:
Sven Riethmueller (Attorney, member of New York and Massachusetts Bars), Foley & Lardner LLP
Dr. Irina Staatz-Granzer, Staatz Business Development and Strategy
Professor Dr. Christof Hettich (Rechtsanwalt), Rittershaus
Related Insights
June 18, 2025
Energy Current
Texas Energizes Nuclear Energy Strategy with Passage of Three Key Bills
The Texas Legislature recently passed three key bills: House Bill 14 (H.B. 14); Senate Bill 1061 (S.B. 1061); and Senate Bill 1535 (S.B….
June 18, 2025
Energy Current
FERC Issues Guidance on Treatment of Criminal Regulatory Offenses
On June 16, 2025, the Federal Energy Regulatory Commission (FERC) issued a Notice of Guidance regarding the consistency of its existing…
June 18, 2025
Foley Viewpoints
Legal Reasoning Still a Struggle for LLMs
The authors in this paper created a benchmark including long-form, open-ended questions and multiple-choice questions to evaluate the…